SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for ALLIENT INC (ALNT) (CIK 0000046129) (ALNT) — Oct 1, 2021

ALLIENT INC (ALNT) (CIK 0000046129)
Date: Oct. 1, 2021 · CIK: 0000046129 · Accession: 0000000000-21-011991

Regulatory Compliance Financial Reporting Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-259840

Date
October 1, 2021
Author
Richard S. Warzala
Form
UPLOAD
Company
ALLIENT INC (ALNT) (CIK 0000046129)

Letter

United States securities and exchange commission logo October 1, 2021 Richard S. Warzala President, Chief Executive Officer and Chairman of the Board ALLIED MOTION TECHNOLOGIES INC 495 Commerce Drive Amherst, New York 14228 Re:ALLIED MOTION TECHNOLOGIES INC Registration Statement on Form S-3 Filed September 28, 2021 File No. 333-259840 Dear Mr. Warzala: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gary Guttenberg at 202 551 6477 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
United States securities and exchange commission logo
October 1, 2021
Richard S. Warzala
President, Chief Executive Officer and Chairman of the Board
ALLIED MOTION TECHNOLOGIES INC
495 Commerce Drive
Amherst, New York 14228
Re:ALLIED MOTION TECHNOLOGIES INC
Registration Statement on Form S-3
Filed September 28, 2021
File No. 333-259840
Dear Mr. Warzala:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Gary Guttenberg at 202 551 6477 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences